506 related articles for article (PubMed ID: 28032590)
1. Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.
Ji Z; Su J; Wu D; Peng H; Zhao W; Nlong Zhao B; Zhou X
Oncotarget; 2017 Jan; 8(5):7647-7665. PubMed ID: 28032590
[TBL] [Abstract][Full Text] [Related]
2. Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling.
Su J; Zhang L; Zhang W; Choi DS; Wen J; Jiang B; Chang CC; Zhou X
PLoS One; 2014; 9(1):e85059. PubMed ID: 24475036
[TBL] [Abstract][Full Text] [Related]
3. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
Lam C; Ferguson ID; Mariano MC; Lin YT; Murnane M; Liu H; Smith GA; Wong SW; Taunton J; Liu JO; Mitsiades CS; Hann BC; Aftab BT; Wiita AP
Haematologica; 2018 Jul; 103(7):1218-1228. PubMed ID: 29622655
[TBL] [Abstract][Full Text] [Related]
4. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Catley L; Tai YT; Shringarpure R; Burger R; Son MT; Podar K; Tassone P; Chauhan D; Hideshima T; Denis L; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2004 Dec; 64(23):8746-53. PubMed ID: 15574786
[TBL] [Abstract][Full Text] [Related]
5. Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.
Bam R; Khan S; Ling W; Randal SS; Li X; Barlogie B; Edmondson R; Yaccoby S
BMC Cancer; 2015 Nov; 15():864. PubMed ID: 26545722
[TBL] [Abstract][Full Text] [Related]
6. Targeting SDF-1 in multiple myeloma tumor microenvironment.
Bouyssou JM; Ghobrial IM; Roccaro AM
Cancer Lett; 2016 Sep; 380(1):315-8. PubMed ID: 26655999
[TBL] [Abstract][Full Text] [Related]
7. Effects of DTX3L on the cell proliferation, adhesion, and drug resistance of multiple myeloma cells.
Shen Y; Sun Y; Zhang L; Liu H
Tumour Biol; 2017 Jun; 39(6):1010428317703941. PubMed ID: 28653881
[TBL] [Abstract][Full Text] [Related]
8. Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.
Ramasamy K; Khatun H; Macpherson L; Caley MP; Sturge J; Mufti GJ; Schey SA; Calle Y
Br J Haematol; 2012 Jun; 157(5):564-79. PubMed ID: 22428569
[TBL] [Abstract][Full Text] [Related]
9. The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro.
Cheung WC; Van Ness B
Leukemia; 2001 Feb; 15(2):264-71. PubMed ID: 11236942
[TBL] [Abstract][Full Text] [Related]
10. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.
Belloni D; Heltai S; Ponzoni M; Villa A; Vergani B; Pecciarini L; Marcatti M; Girlanda S; Tonon G; Ciceri F; Caligaris-Cappio F; Ferrarini M; Ferrero E
Haematologica; 2018 Apr; 103(4):707-716. PubMed ID: 29326121
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
[TBL] [Abstract][Full Text] [Related]
12. HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.
Borsi E; Perrone G; Terragna C; Martello M; Zamagni E; Tacchetti P; Pantani L; Brioli A; Dico AF; Zannetti BA; Rocchi S; Cavo M
Exp Cell Res; 2014 Nov; 328(2):444-55. PubMed ID: 25257607
[TBL] [Abstract][Full Text] [Related]
13. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
Monaghan KA; Khong T; Burns CJ; Spencer A
Leukemia; 2011 Dec; 25(12):1891-9. PubMed ID: 21788946
[TBL] [Abstract][Full Text] [Related]
14. A preclinical assay for chemosensitivity in multiple myeloma.
Khin ZP; Ribeiro ML; Jacobson T; Hazlehurst L; Perez L; Baz R; Shain K; Silva AS
Cancer Res; 2014 Jan; 74(1):56-67. PubMed ID: 24310398
[TBL] [Abstract][Full Text] [Related]
15. Synergistic combination therapy with cotylenin A and vincristine in multiple myeloma models.
Takahashi T; Honma Y; Miyake T; Adachi K; Takami S; Okada M; Kumanomidou S; Ikejiri F; Jo Y; Onishi C; Kawakami K; Moriyama I; Inoue M; Tanaka J; Suzumiya J
Int J Oncol; 2015 Apr; 46(4):1801-9. PubMed ID: 25672400
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.
Bar-Natan M; Stroopinsky D; Luptakova K; Coll MD; Apel A; Rajabi H; Pyzer AR; Palmer K; Reagan MR; Nahas MR; Karp Leaf R; Jain S; Arnason J; Ghobrial IM; Anderson KC; Kufe D; Rosenblatt J; Avigan D
Br J Haematol; 2017 Mar; 176(6):929-938. PubMed ID: 28107546
[TBL] [Abstract][Full Text] [Related]
17. Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model.
Hayun M; Saida H; Albeck M; Peled A; Haran-Ghera N; Sredni B
Exp Hematol; 2009 May; 37(5):593-603. PubMed ID: 19375650
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
Nefedova Y; Landowski TH; Dalton WS
Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
[TBL] [Abstract][Full Text] [Related]
19. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment.
Azab AK; Quang P; Azab F; Pitsillides C; Thompson B; Chonghaile T; Patton JT; Maiso P; Monrose V; Sacco A; Ngo HT; Flores LM; Lin CP; Magnani JL; Kung AL; Letai A; Carrasco R; Roccaro AM; Ghobrial IM
Blood; 2012 Feb; 119(6):1468-78. PubMed ID: 22096244
[TBL] [Abstract][Full Text] [Related]
20. Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation.
McMillin DW; Delmore J; Negri J; Ooi M; Klippel S; Miduturu CV; Gray NS; Richardson PG; Anderson KC; Kung AL; Mitsiades CS
PLoS One; 2011; 6(7):e20226. PubMed ID: 21750699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
